India’s drug regulator granted emergency use approval for Zydus Cadila’s Covid-19 vaccine, the world’s first DNA shot against the coronavirus, in adults and children aged 12 years and older.

Bristol Myers Squibb’s Opdivo (nivolumab) 240 mg every two weeks or 480 mg every four weeks (injection for intravenous use) was approved by the U.S. Food and Drug Administration for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence after undergoing radical resection, regardless of prior neoadjuvant chemotherapy, nodal involvement or PD-L1 status.

The UK drug regulator approved an antibody cocktail developed by Regeneron and Roche to prevent and treat Covid-19, as the nation battles rising hospitalizations due to the more infectious Delta variant.

The U.S. Food and Drug Administration approved Pfizer’s tick-borne encephalitis vaccine TICOVAC to prevent TBE in people aged 1 year and older.

Merck won U.S. Food and Drug Administration approval for a first-of-its-kind oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor that is used to treat a rare genetic disease that causes benign and cancerous tumors in blood vessels associated with renal cell carcinoma.

The U.S. Food and Drug Administration approved Abbott’s Amplatzer Amulet Left Atrial Appendage Occluder to treat people with atrial fibrillation (AFib) who are at risk of ischemic stroke.

The U.S. Food and Drug Administration approved Jazz Pharmaceuticals’ Xywav for idiopathic hypersomnia in adults.

The U.S. Food and Drug Administration approved the combination of Merck’s anti-PD-1 therapy Keytruda plus Eisai’s orally available multiple receptor tyrosine kinase inhibitor Lenvima for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).

The U.S. Food and Drug Administration approved Nexviazyme (avalglucosidase alfa-ngpt) for the treatment of patients 1 year of age and older with late-onset Pompe disease, a progressive and debilitating muscle disorder that impairs a person’s ability to move and breathe.

Biogen Inc. and partner Eisai Co. Ltd. on July 29 revealed the design of an upcoming study of their controversial Alzheimer’s treatment, Aduhelm.